All News

Patients with lung cancer are encouraged to participate in the new modules that will capture data to help gain insights into their treatment path and treatment options.

While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.

When we lose a family member to cancer, grief may seem interminable. With time, though, the memories become golden, and there is no reason to forget the good because of the bad.

Friends would often ask me why I was doing all this running and biking. I had no answer for them. Now, looking back, I know that God was preparing me for the biggest race of my life: my cancer journey!

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

The label of being a cancer survivor can be simple, but underneath it can mean something so different to each person. Only you can choose what the idea of survivorship means to your journey.

A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.

Here is a list of clinical trials that are currently happening within the cervical cancer space.

Something I have often done when approaching a problem or setback in life is to find a success story that helps to motivate me and inspire me along my own journey.

Here is a list of clinical trials that are currently happening within the kidney cancer space.

Choosing a gift for the person with cancer can be challenging. In this post, survivor Bonnie Annis offers some helpful information by sharing thoughts as she remembers her own past Christmases.

From better breast cancer screening options for service members and their families to a Christmas display that’s raising cancer awareness, here’s what is making headlines in the cancer space this week.

Two-time cancer survivor Anne Weber feels fortunate to have learned of her BRCA2 gene mutation, as it led to an early diagnosis of aggressive breast cancer.

New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.

A new study suggests the common pill could help prevent deaths from cancer, but it’s not without it's share of side effects.

Rebuilding your life after a kick in the gut is all about your mindset.

Immunotherapy in combination with chemotherapy is becoming a popular treatment for patients with lung cancer, but patients need to understand the side effects.

In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.

What do erasers, drawings, cancer and life all have in common? More than you might think.

The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.

Marijuana use is gaining cultural acceptance as a way to ease discomfort in patients with cancer, but is it safety is still unclear.

How do you heal your mind when faced with cognitive impairment after cancer treatment?

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.

The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.

Living life means living with the risk of cancer. It is interesting to contemplate how the cards are dealt even as we try to outwit fate.

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

Here are the top five CURE® stories for November 2019.

Patient advocate and lung cancer survivor Nancy Cohen discusses living with stage 4 lung cancer.